[{"arm_notes": "", "treatment_id": null, "treatment_name": "AP1189; 100mg once daily during fasting. The mode of administration will be orally or through a nasoenteral catather if needed. The predicted duration of the treatment is 14 days. Six patients will be taking the drug in fase 1 to test for tolerability and safety. In fase 2; 32 randomized patients will use the drug and18 randomized patients will be taking placebo in the same manner as the drug under investigation.;D26.371;11350", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 107, "treatment_name": "Ap1189", "treatment_type": "Anti-inflammatories", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]